GL1X · GenesisL1 explorer

Research workbench

Fab structure of anti-vaccinia virus D8L antigen mouse IGG2A LA5

Analyse Fab structure of anti-vaccinia virus D8L antigen mouse IGG2A LA5 in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
4EBQ
Type
protein
Length
429 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Anti-vaccinia D8L antigen monoclonal IGG2A antibody LA5, heavy chain; Anti-vaccinia D8L…
Ligands
CL, PO4
Pockets
5 · best druggability 0.55

Structure

x-ray diffraction · 2 distinct chains · 7% helix, 52% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
HAnti-vaccinia D8L antigen monoclonal IGG2A antibody LA5, heavy chainprotein2188% helix, 52% strand—
LAnti-vaccinia D8L antigen monoclonal IGG2A antibody LA5, light chainprotein2117% helix, 52% strand—

Ligands and binding sites

  • CL · Chloride ion · ion · 2 copies · chains H
  • PO4 · Phosphate ion · ion · chains H
  • EDO · 1,2-ethanediol · additive · 2 copies · chains H, L
  • GOL · Glycerol · additive · chains H, L

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

5 pockets found on a 1 Å grid, 1 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
13550.550.7556EDO
21210.380.7423empty
3620.360.7817empty
4720.310.7422empty
5510.270.7414empty

Interfaces

1 interface between chains.

  • H–L · 1934 Ų buried · 12 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 5 disulfide (disulfide).

Compared structures

  • 4EBQ · Fab structure of anti-Vaccinia virus D8L antigen mouse IgG2a LA5 · the same entry in another collection · chain H against H, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.